Thermo Fisher Scientific (TMO) continues to remain a significant player in the biotech market. Notable occurrences include a
collaboration with the Chan Zuckerberg Institute for advanced biological imaging, the
introduction of the Vulcan™ Automated Lab, and an approved
acquisition of Solventum’s Purification and Filtration Business. Expectations are high for the company, despite a fell in Q4. TMO continues to be listed among the best stocks to invest in, within sectors such as Diagnostics, Diabetes, Healthcare Dividends, and fundamental stocks. The company completed a
$1B share repurchase, and looks forward to entering 2025 with robust profit owing to increased demand for its tools and services. However, some caution over stock underperformance and insider share selling has been reported. Reinforcing its presence in the European Market, TMO accelerated its goal for
renewable electricity use. Furthermore, the company is extending its reach in the health sector, utilizing next-generation sequencing technology for myeloid cancer research and treatment. Sales struggles have been reported in two key units leading to a dip in profit and revenue, yet the company remains bullish with a new
$4B share buyback program.
Thermo Fisher Scientific TMO News Analytics from Thu, 11 Jul 2024 07:00:00 GMT to Fri, 28 Mar 2025 23:08:41 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 2
